TESARO, Inc. (NASDAQ:TSRO)‘s stock had its “outperform” rating reissued by Wells Fargo & Company in a research report issued on Sunday.

TSRO has been the topic of a number of other research reports. BidaskClub downgraded TESARO from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Robert W. Baird restated a “neutral” rating on shares of TESARO in a report on Tuesday, June 6th. Bank of America Corporation restated a “buy” rating and issued a $154.00 price objective on shares of TESARO in a report on Tuesday, June 20th. Wedbush upgraded TESARO to an “outperform” rating and set a $168.00 price objective on the stock in a report on Monday, June 5th. Finally, ValuEngine downgraded TESARO from a “hold” rating to a “sell” rating in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. TESARO has a consensus rating of “Buy” and an average price target of $175.52.

Shares of TESARO (TSRO) opened at 113.86 on Friday. The stock’s market capitalization is $6.17 billion. The firm’s 50-day moving average is $125.98 and its 200 day moving average is $147.86. TESARO has a 1-year low of $83.26 and a 1-year high of $192.94.

TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by $0.30. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same quarter in the prior year, the company posted ($1.28) EPS. The company’s quarterly revenue was down 17.6% on a year-over-year basis. On average, analysts expect that TESARO will post ($8.70) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “TESARO, Inc. (TSRO) Receives “Outperform” Rating from Wells Fargo & Company” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/20/tesaro-inc-tsro-receives-outperform-rating-from-wells-fargo-company.html.

In other news, VP Edward C. English sold 8,500 shares of the firm’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total value of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares in the company, valued at $748,155.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 40.50% of the company’s stock.

Large investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio increased its stake in shares of TESARO by 82.4% in the second quarter. Public Employees Retirement System of Ohio now owns 36,667 shares of the biopharmaceutical company’s stock valued at $5,128,000 after buying an additional 16,569 shares during the last quarter. Intellectus Partners LLC increased its stake in shares of TESARO by 17.7% in the second quarter. Intellectus Partners LLC now owns 6,310 shares of the biopharmaceutical company’s stock valued at $883,000 after buying an additional 950 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of TESARO by 20.8% in the second quarter. California State Teachers Retirement System now owns 68,090 shares of the biopharmaceutical company’s stock valued at $9,523,000 after buying an additional 11,706 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of TESARO by 291.7% in the second quarter. Cubist Systematic Strategies LLC now owns 7,105 shares of the biopharmaceutical company’s stock valued at $994,000 after buying an additional 5,291 shares during the last quarter. Finally, PointState Capital LP bought a new stake in shares of TESARO during the second quarter valued at about $85,971,000.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.